137 related articles for article (PubMed ID: 16261363)
1. Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity.
Fukasawa T; Yasui-Furukori N; Suzuki A; Inoue Y; Tateishi T; Otani K
Eur J Clin Pharmacol; 2005 Dec; 61(11):791-5. PubMed ID: 16261363
[TBL] [Abstract][Full Text] [Related]
2. Effects of the CYP2C19 genotype and cigarette smoking on the single oral dose pharmacokinetics and pharmacodynamics of estazolam.
Aoshima T; Fukasawa T; Otsuji Y; Okuyama N; Gerstenberg G; Miura M; Ohkubo T; Sugawara K; Otani K
Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):535-8. PubMed ID: 12691790
[TBL] [Abstract][Full Text] [Related]
3. Notable Drug-Drug Interaction Between Etizolam and Itraconazole in Poor Metabolizers of Cytochrome P450 2C19.
Yamamoto T; Furihata K; Hisaka A; Moritoyo T; Ogoe K; Kusayama S; Motohashi K; Mori A; Iwatsubo T; Suzuki H
J Clin Pharmacol; 2017 Nov; 57(11):1491-1499. PubMed ID: 28679023
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism.
Araki K; Yasui-Furukori N; Fukasawa T; Aoshima T; Suzuki A; Inoue Y; Tateishi T; Otani K
Eur J Clin Pharmacol; 2004 Aug; 60(6):427-30. PubMed ID: 15232663
[TBL] [Abstract][Full Text] [Related]
5. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
Uno T; Sugimoto K; Sugawara K; Tateishi T
Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
[TBL] [Abstract][Full Text] [Related]
6. The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects.
Jiang ZP; Shu Y; Chen XP; Huang SL; Zhu RH; Wang W; He N; Zhou HH
Eur J Clin Pharmacol; 2002 May; 58(2):109-13. PubMed ID: 12012142
[TBL] [Abstract][Full Text] [Related]
7. The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects.
Bramness JG; Skurtveit S; Gulliksen M; Breilid H; Steen VM; Mørland J
Eur J Clin Pharmacol; 2005 Aug; 61(7):499-506. PubMed ID: 16021435
[TBL] [Abstract][Full Text] [Related]
8. Single oral dose pharmacokinetics of quazepam is influenced by CYP2C19 activity.
Fukasawa T; Yasui-Furukori N; Aoshima T; Suzuki A; Tateishi T; Otani K
Ther Drug Monit; 2004 Oct; 26(5):529-33. PubMed ID: 15385836
[TBL] [Abstract][Full Text] [Related]
9. Induction of the metabolism of etizolam by carbamazepine in humans.
Kondo S; Fukasawa T; Yasui-Furukori N; Aoshima T; Suzuki A; Inoue Y; Tateishi T; Otani K
Eur J Clin Pharmacol; 2005 May; 61(3):185-8. PubMed ID: 15776275
[TBL] [Abstract][Full Text] [Related]
10. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
11. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.
Yin OQ; Tomlinson B; Chow MS
Clin Pharmacol Ther; 2005 Oct; 78(4):370-7. PubMed ID: 16198656
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans.
Kobayashi K; Morita J; Chiba K; Wanibuchi A; Kimura M; Irie S; Urae A; Ishizaki T
Pharmacogenetics; 2004 Aug; 14(8):549-56. PubMed ID: 15284537
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype.
Jan MW; ZumBrunnen TL; Kazmi YR; VanDenBerg CM; Desai HD; Weidler DJ; Flockhart DA
Drug Metabol Drug Interact; 2002; 19(1):1-11. PubMed ID: 12222750
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
Desta Z; Zhao X; Shin JG; Flockhart DA
Clin Pharmacokinet; 2002; 41(12):913-58. PubMed ID: 12222994
[TBL] [Abstract][Full Text] [Related]
15. The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers.
Uno T; Sugimoto K; Sugawara K; Tateishi T
J Clin Pharm Ther; 2008 Feb; 33(1):67-73. PubMed ID: 18211619
[TBL] [Abstract][Full Text] [Related]
16. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia.
Inomata S; Nagashima A; Itagaki F; Homma M; Nishimura M; Osaka Y; Okuyama K; Tanaka E; Nakamura T; Kohda Y; Naito S; Miyabe M; Toyooka H
Clin Pharmacol Ther; 2005 Dec; 78(6):647-55. PubMed ID: 16338280
[TBL] [Abstract][Full Text] [Related]
17. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
Yasui-Furukori N; Takahata T; Nakagami T; Yoshiya G; Inoue Y; Kaneko S; Tateishi T
Br J Clin Pharmacol; 2004 Apr; 57(4):487-94. PubMed ID: 15025747
[TBL] [Abstract][Full Text] [Related]
18. Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes.
Miura M; Kagaya H; Tada H; Uno T; Yasui-Furukori N; Tateishi T; Suzuki T
Br J Clin Pharmacol; 2006 Mar; 61(3):315-20. PubMed ID: 16487225
[TBL] [Abstract][Full Text] [Related]
19. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
[TBL] [Abstract][Full Text] [Related]
20. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.
Wang G; Lei HP; Li Z; Tan ZR; Guo D; Fan L; Chen Y; Hu DL; Wang D; Zhou HH
Eur J Clin Pharmacol; 2009 Mar; 65(3):281-5. PubMed ID: 18982321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
